Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049830 | 1.00 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KCNA5KCNE1 | |
| Bromide SCHEMBL18632030 | 0.97 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3KCNA5KCNE1 | |
| SCHEMBL4316276 | 0.86 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3KCNA5KCNE1 | |
| SCHEMBL331474 | 0.84 | — | — | |
| SCHEMBL4099842 | 0.82 | — | — | |
| SCHEMBL9185638 | 0.81 | SLC6A3 (0.56) | SLC6A2SLC6A4SLC6A3KCNA5KCNE1 | |
| SCHEMBL1582061 | 0.80 | — | — | |
| SCHEMBL6985204 | 0.80 | — | — | |
| SCHEMBL6985202 | 0.80 | — | — | |
| SCHEMBL29404365 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116365-B2 | Heterocyclic compounds and uses thereof | Opna Bio SA (CH) | 2024-10-15 | — | — | US | disclosed |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2022-11-10 | — | — | US | disclosed |
| EP-4071149-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Immuno Oncology, SA (CH) | 2022-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116365-B2 | Heterocyclic compounds and uses thereof | CYP11B2, CYP11B1, UGT2B7 | SLC6A2 2213/4885SLC6A4 3035/4885SLC6A3 2971/4885 |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, UGT2B7 | SLC6A2 2213/4885SLC6A4 3035/4885SLC6A3 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.